MahaFDA conducted 2,164 inspections to stop black marketing against Covid-19 medicines

Due to increase in the black marketing in Covid-19 medicines like tocilizumab, the Maharashtra Food and Drug Administration (FDA) has increased inspections and recently conducted 2,164 inspections from the period of July 14, 2020 and August 03, 2020.
16 persons have been also booked for the sale of life-saving essential COVID-19 medicines at overpriced rates.

Maharashtra FDA and Bandra Police also trapped and caught a resident of Kashipur, Uttarakhand who was found selling tocilizumab on increased price of Rs.1 lakh per vial which has the MRP of Rs. 40,000. Total 15 vials of tocilizumab were seized from him. These injections were brought from Delhi market as per pre-investigation.

Four raids have been conducted by the State drug regulator over a period of 14 days earlier in joint operations with police as the black marketing had involvement of unscrupulous traders who were selling drugs without any drug license. The black marketers had connections with company officials and marketing representatives of reputed companies.
State FDA minister Rajendra Shingne said, “the government plans to publish the price and availability of the drugs online for transparency. These drugs have been given emergency use authorization by the Drugs Controller General of India (DCGI) for critically ill or lab suspected COVID-19 patients. Maharashtra FDA caught five people red-handed selling remdesivir injection at Rs. 25,000 (the Cipla’s branded injection Cipremi (remdesivir) MRP is Rs. 4,000) and tocilizumab sold under Actemra by Cipla in India which has MRP of Rs. 40,545 was unethically sold at Rs. 80,000 much higher than market retail prices without license in violation of different sections of the Indian Penal Code (IPC), DPCO-2013, EC Act and D&C Rules.”

An action plan was enforced by the Maharashtra FDA started the massive drive to curb black marketing following under the guidance of Dr. Rajendra Shingane, Maharashtra FDA Minister, Rajendra Yadravkar, Minister of State, Maharashtra FDA in consultation with Maharashtra FDA Vigilance Commissioner Sunil Bharadwaj.

  • Related Posts

    IPC releases draft NFI-2026 to promote rational use of medicines

    Ghaziabad:- The Indian Pharmacopoeia Commission (IPC) has taken a significant step toward strengthening public health systems with the draft release of the National Formulary of India (NFI) 2026, a comprehensive…

    Laser rescued an Imperiled Food Pipe in Sir Ganga Ram Hospital

    An Impacted Denture accidently  had lodged inside it New Delhi: In a remarkable medical achievement, doctors at Sir Ganga Ram Hospital successfully removed an impacted dental plate that had accidentally…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    IPC releases draft NFI-2026 to promote rational use of medicines

    IPC releases draft NFI-2026 to promote rational use of medicines